Regeneron Pharmaceuticals (REGN) Cost of Revenue (2009 - 2026)

Regeneron Pharmaceuticals' Cost of Revenue history runs 18 years deep, the most recent figure standing at $296.0 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 48.89% year-over-year to $296.0 million; the TTM figure through Mar 2026 stood at $950.0 million (down 5.97% YoY), while the FY2025 annual figure was $959.9 million, down 11.72% from the prior year.
• Cost of Revenue was $296.0 million for Q1 2026 at Regeneron Pharmaceuticals, up from $137.8 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $326.8 million in Q4 2024 to a low of $137.8 million in Q4 2025.
• Historically, Cost of Revenue has averaged $224.0 million across 5 years, with a median of $212.5 million in 2023.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue sank 70.63% in 2022, then jumped 55.47% in 2024.
• A 5-year view of Cost of Revenue shows it stood at $238.4 million in 2022, then slipped by 11.83% to $210.2 million in 2023, then surged by 55.47% to $326.8 million in 2024, then tumbled by 57.83% to $137.8 million in 2025, then soared by 114.8% to $296.0 million in 2026.
• The last three Cost of Revenue figures came in at $296.0 million (Q1 2026), $137.8 million (Q4 2025), and $240.6 million (Q3 2025), per Business Quant data.